May 9, 2017 | Hong Kong-based investment firm AID Partners Capital Ltd will acquire Israeli medical diagnostic company GeneSort for $23 million. The deal will provide GeneSort with additional resources and support as is seeks to expand into Southeast Asia and other global markets. Moshe Hogeg’s tech focused venture capital firm Singulariteam fund is the largest investor in GeneSort, having invested $2.2 million in the company. GeneSort is a molecular diagnostics company focused on integrating molecular genomics with personalized therapeutic approaches. GeneSort also recently signed a development contract with the government of Malta, and also won a contract with the Israeli government to deploy diagnostic testing in the country.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments